Skip to main content

Table 2 COPD prevalence (%)* in major demographic subgroups using the fixed ratio criterion (FEV1/FVC<0.70)

From: Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007–2010

 

Fixed ratio criterion (FEV1/FVC<0.70)

Estimates based on pre- bronchodilator spirometry dataa

Estimates based on pre and post-bronchodilator spirometry datab

Original exam weights (n = 5532)

Weights adjusted for non-response (n = 5532)

Original exam weights (n = 4986)

Pre-BR and Post-BR weights adjusted for non-response (n = 4986)

Post-BR missing data imputed then Pre-BR weights adjusted for non-response (n = 5532)

Overall

20.3 (1.1)

20.9 (1.1)

8.3 (0.7)

14.0 (1.0)

13.7 (0.8)

   Stage I (Mild)c

10.9 (0.7)

11.0 (0.7)

5.0 (0.6)

7.9 (0.8)

7.2 (0.5)

   Stage II (Moderate)c

7.8 (0.6)

8.0 (0.6)

2.4 (0.2)

4.7 (0.5)

5.0 (0.4)

   Stage III and IV (Severe/Very Severe)c

1.1 (0.2)

1.2 (0.2)

0.3 (0.1)

0.7 (0.2)

0.8 (0.2)

Age

     

   40–59

15.4 (1.2)

15.6 (1.2)

6.2 (0.7)

9.4 (1.0)

9.2 (0.9)

   60–79

30.7 (1.3)

31.2 (1.3)

13.3 (1.1)

23.0 (1.7)

22.6 (1.2)

Gender

     

   Male

24.1 (1.2)

24.8 (1.3)

11.4 (0.9)

17.4 (1.2)

17.4 (1.0)

   Female

16.7 (1.3)

17.3 (1.3)

5.4 (0.6)

10.8 (1.3)

10.4 (0.8)

Race and ethnic origin

     

   Non-Hispanic white

22.5 (1.2)

22.9 (1.2)

9.5 (0.8)

15.0 (1.1)

14.9 (0.9)

   Non-Hispanic black

17.4 (1.3)

18.0 (1.4)

6.9 (0.9)

14.1 (2.0)

12.8 (1.3)

   Mexican-American

10.1 (.7)

10.4 (0.7)

2.7 (0.6)

5.4 (1.1)

5.8 (0.8)

  1. *Standard errors of the estimates are given in parentheses.
  2. Adults Aged 40–79 Years: NHANES 2007-10.
  3. aEstimates based on pre-bronchodilator included those who completed the pre-bronchodilator test plus those persons excluded from pre-BR spirometry who had a medical diagnosis of emphysema or chronic bronchitis plus used daytime supplemental oxygen therapy.
  4. bEstimates based on pre and post-bronchodilator included those who completed the pre-bronchodilator test and were not selected for the post-bronchodilator test (no disease), plus those persons who completed the post-bronchodilator test, plus those persons excluded from pre-BR spirometry who had a medical diagnosis of emphysema or chronic bronchitis plus used daytime supplemental oxygen therapy. The 546 persons who did not complete the post-bronchodilator test are included in the numerator of the imputed estimates as their post-bronchodilator data was multiply imputed.
  5. cSpirometric classification used the following cutoffs per GOLD specifications: Mild (Stage 1): PPFEV1 ≥ 80%, Moderate (Stage 2): 50% ≤PPFEV1 < 80%, Severe and Very severe (Stages 3 and 4): PPFEV1 < 50%.